Discontinued — last reported Q1 '18
Boston Scientific Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments increased by 6.2% to $310.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 12.3%, from $276.00M to $310.00M. Over 4 years (FY 2020 to FY 2024), Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments shows an upward trend with a 10.9% CAGR.
equity_securities_no_fv_downward_adj| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $175.00M | $164.00M | $142.00M | $165.00M | $159.00M | $171.00M | $219.00M | $219.00M | $215.00M | $207.00M | $194.00M | $218.00M | $243.00M | $276.00M | $277.00M | $297.00M | $292.00M | $310.00M |
| QoQ Change | — | -6.3% | -13.4% | +16.2% | -3.6% | +7.5% | +28.1% | +0.0% | -1.8% | -3.7% | -6.3% | +12.4% | +11.5% | +13.6% | +0.4% | +7.2% | -1.7% | +6.2% |
| YoY Change | — | — | — | — | -9.1% | +4.3% | +54.2% | +32.7% | +35.2% | +21.1% | -11.4% | -0.5% | +13.0% | +33.3% | +42.8% | +36.2% | +20.2% | +12.3% |